Re: patients in clinical trial overwhelmingly prefer subcutaneous herceptin administr
Hi 'lizbeth,
I pulled up the study on clinicaltrials.gov and the actual table description of the arms is poorly done (it shows one arm noted to be HER2 positive patients receiving lapatinib and trastuzumab only, with the other arm being ER/PR positive and receiving letrozole only, and does not show any patients in the trial who happen to be both HR positive and HER2 positive) while the initial description indicates the trial is designed - To establish the safety and tolerability of an extended regimen of lapatinib + trastuzumab, with or without endocrine therapy
It is also described as being an "extension" study, in which the patients chosen are from an earlier study (I'm not sure what the treatment in the arms were for that earlier study, but it sounds like these were patients who have already completed some lapatinib and trastuzumab but I don't know if that earlier study required any administration of chemotherapy?)
A.A.
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|